Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma.
OBJECTIVE
The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma.


METHODS
Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg icotinib orally three times a day. Progression of disease, intolerable adverse reactions, and number of deaths were recorded.


RESULTS
For all the patients, the remission rate of icotinib was 67.8% and the disease control rate was 96.4%. The median overall survival time of patients was 21.2 months, and the median progression-free survival time of patients was 10.9 months. Only mild adverse events of grade 1/2 were observed during the treatment.


CONCLUSIONS
Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma.
Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Jianping
J
Xu
Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Xiaoyan
X
Liu
Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Sheng
S
Yang
Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Xiangru
X
Zhang
Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yuankai
Y
Shi
brain metastases; icotinib; lung adenocarcinoma